Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Antibe Therapeutics (ATBPF)

Antibe Therapeutics (ATBPF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 106,768
  • Shares Outstanding, K 386,000
  • Annual Sales, $ 7,510 K
  • Annual Income, $ -14,540 K
  • 60-Month Beta 0.27
  • Price/Sales 14.26
  • Price/Cash Flow N/A
  • Price/Book 4.82
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.06
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/25/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2711 +2.03%
on 09/18/20
0.3274 -15.52%
on 08/21/20
-0.0363 (-11.60%)
since 08/18/20
3-Month
0.2711 +2.03%
on 09/18/20
0.3730 -25.84%
on 08/06/20
-0.0686 (-19.87%)
since 06/18/20
52-Week
0.2711 +2.03%
on 09/18/20
0.6404 -56.81%
on 06/01/20
-0.0116 (-4.02%)
since 09/18/19

Most Recent Stories

More News
Antibe Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that Dan...

ATE.VN : 0.365 (unch)
ATBPF : 0.2766 (-0.29%)
MHMNF : 54.5000 (unch)
Antibe Therapeutics to Present at Upcoming Conferences

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announced that the Company will be presenting at two conferences:

ATE.VN : 0.365 (unch)
ATBPF : 0.2766 (-0.29%)
Antibe Therapeutics Reports Q1 2021 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Monday, August 24 for the fiscal quarter ended June 30, 2020. The Company's unaudited...

ATE.VN : 0.365 (unch)
ATBPF : 0.2766 (-0.29%)
Antibe Therapeutics Announces Results of Annual and Special Meeting

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual and special meeting held earlier today. All resolutions outlined in the management information circular...

ATE.VN : 0.365 (unch)
ATBPF : 0.2766 (-0.29%)
Antibe Therapeutics Engages Stern IR for Investor Relations Services

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announces that it has engaged Stern Investor Relations, Inc. ("Stern IR") to expand the Company's investor relations program and support efforts...

ATE.VN : 0.365 (unch)
ATBPF : 0.2766 (-0.29%)
Antibe Therapeutics Provides Corporate Update

Antibe Therapeutics Inc.:

ATBPF : 0.2766 (-0.29%)
ATE.VN : 0.365 (unch)
IIROC Trading Resumption - ATE

Trading resumes in:

ATBPF : 0.2766 (-0.29%)
Antibe Therapeutics Announces $25 Million Bought Deal Unit Offering

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by Bloom Burton Securities Inc. and...

ATBPF : 0.2766 (-0.29%)
ATE.VN : 0.365 (unch)
Antibe Therapeutics to Host Conference Call to Discuss Positive Results of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) will host a conference call Thursday, June 4 at 10:00 am ET to discuss the recent positive results of the Phase 2B dose-ranging, efficacy study for ATB-346....

ATBPF : 0.2766 (-0.29%)
ATE.VN : 0.365 (unch)
Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346

ATBPF : 0.2766 (-0.29%)
ATE.VN : 0.365 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ATBPF with:

Key Turning Points

2nd Resistance Point 0.2873
1st Resistance Point 0.2820
Last Price 0.2766
1st Support Level 0.2712
2nd Support Level 0.2657

See More

52-Week High 0.6404
Fibonacci 61.8% 0.4993
Fibonacci 50% 0.4557
Fibonacci 38.2% 0.4122
Last Price 0.2766
52-Week Low 0.2711

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar